You are leaving Medscape Education
Cancel Continue
Log in to save activities Your saved activities will show here so that you can easily access them whenever you're ready. Log in here CME & Education Log in to keep track of your credits.
 

CPD

SGLT2 Inhibitors and Other Classes of Therapies in HFpEF: Examining The Totality of Clinical Data

  • Authors: Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC; Stefan D. Anker, MD, PhD; Biykem Bozkurt, MD, PhD
  • CPD Released: 12/23/2021
  • Valid for credit through: 12/23/2022
Start Activity

  • Credits Available

    Non-US Physicians - maximum of 0.50 CPD

    You Are Eligible For

    • Letter of Completion

Target Audience and Goal Statement

This educational activity is intended for an international audience of non-US cardiologists and primary care physicians.

The goal of this activity is to put the results of recent data on sodium-glucose cotransporter-2 (SGLT2) inhibition in patients with heart failure with preserved ejection fraction (HFpEF) in context with older HFpEF trials.

Upon completion of this activity, participants will:

  • Have increased knowledge regarding the
    • Differences between historical trials and modern trials in HFpEF
    • Latest clinical trial data for SGLT2 inhibition in HFpEF
    • Potential explanations for the success of SGLT2 inhibition in HFpEF


Disclosures

WebMD Global requires each individual who is in a position to control the content of one of its educational activities to disclose any relevant financial relationships occurring within the past 12 months that could create a conflict of interest.


Faculty

  • Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC

    Senior Consultant Cardiologist
    National Heart Center
    Professor of Medicine
    Duke National University
    Singapore, Singapore

    Disclosures

    Disclosure: Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC, has the following relevant financial relationships:
    Advisor or consultant for: Actelion; Amgen; Applied Therapeutics; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Scientific; Cytokinetics; Darma Inc.; Janssen Research & Development LLC; Merck; Novartis; Novo Nordisk.; Roche Diagnostics; Sanofi
    Grants for clinical research from: AstraZeneca; Bayer; Boston Scientific; Roche Diagnostics

  • Stefan D. Anker, MD, PhD

    Professor of Cardiology & Cachexia Research
    Applied Cachexia Research
    Department of Cardiology
    Charité, Campus Virchow-Klinikum
    Berlin, Germany

    Disclosures

    Disclosure: Stefan D. Anker, MD, PhD, has disclosed the following relevant financial relationships:
    Advisor or consultant for: Abbott; Bayer; Boehringer Ingelheim; Brahms GmbH; Cardiac Dimension; Cordio; Impulse Dynamics; Novartis; Occlutech; Servier; Vifor Pharma
    Speaker or a member of a speakers bureau for: Bayer; Boehringer Ingelheim; Vifor Pharma
    Grants for clinical research from: Abbott; Vifor Pharma

  • Biykem Bozkurt, MD, PhD

    Professor of Medicine-Cardiology
    Baylor College of Medicine
    Houston, Texas, United States

    Disclosures

    Disclosure: Biykem Bozkurt, MD, PhD, has the following relevant financial relationships:
    Advisor or consultant for: Amgen; AstraZeneca; Baxter Healthcare Corporation; Bristol Myers Squibb; Relypsa; Sanofi-Aventis; scPharmaceuticals; Vifor Pharma
    Grants for clinical research from: Clinical Event Committee for GUIDE HF Trial sponsored by Abbott Vascular; Data Safety Monitoring Committee of ANTHEM trial sponsored by Liva Nova

Editor

  • Anne M. Sendaydiego, PharmD

    Medical Education Director, WebMD Global, LLC

    Disclosures

    Disclosure: Anne M. Sendaydiego, PharmD, has disclosed no relevant financial relationships.

Content Reviewer

  • Robert Morris, PharmD

    Associate Director, Accreditation and Compliance

    Disclosures

    Disclosure: Robert Morris, PharmD, has disclosed the following relevant financial relationships:
    Served as an advisor or consultant for: ViiV Healthcare
    Owns stock, stock options, or bonds from: GlaxoSmithKline


Accreditation Statements

    For Physicians

  • The Faculty of Pharmaceutical Medicine of the Royal Colleges of Physicians of the United Kingdom (FPM) has reviewed and approved the content of this educational activity and allocated it 0.50 continuing professional development credits (CPD).

    Contact WebMD Global

For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]


Instructions for Participation and Credit

There are no fees for participating in or receiving credit for this online educational activity. For information about your eligibility to claim credit, please consult your professional licensing board.

This activity is designed to be completed within the time designated on the title page; physicians should claim only those credits that reflect the time actually spent participating in the activity. To successfully earn credit, participants must complete the activity online during the credit eligibility period that is noted on the title page.

Follow these steps to claim a credit certificate for completing this activity:

  1. Read the information provided on the title page regarding the target audience, learning objectives, and author disclosures, read and study the activity content and then complete the post-test questions. If you earn a passing score on the post-test and we have determined based on your registration profile that you may be eligible to claim CPD credit for completing this activity, we will issue you a CPD credit certificate.
  2. Once your CPD credit certificate has been issued, you may view and print the certificate from your CME/CE Tracker. CPD credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of the Medscape Education homepage.

We encourage you to complete an Activity Evaluation to provide feedback for future programming.

You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it. Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print out the tally as well as the certificates by accessing "Edit Your Profile" at the top of your Medscape homepage.

*The credit that you receive is based on your user profile.

CPD

SGLT2 Inhibitors and Other Classes of Therapies in HFpEF: Examining The Totality of Clinical Data

Authors: Carolyn S.P. Lam, MBBS, PhD, FRCP, FAMS, FESC, FACC; Stefan D. Anker, MD, PhD; Biykem Bozkurt, MD, PhDFaculty and Disclosures

CPD Released: 12/23/2021

Valid for credit through: 12/23/2022

processing....

Educational Impact Challenge

The goal of this activity is to put the results of recent data on sodium-glucose cotransporter-2 (SGLT2) inhibition in patients with heart failure with preserved ejection fraction (HFpEF) in context with older HFpEF trials.

Before you begin this activity, please assess your clinical knowledge by completing this brief survey. Answering these questions again after the activity will allow you to see what you learned and to compare your answers with those of your peers.